MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 01-08-2026
Neogen Corporation Total Assets 2011-2026 | NEOG
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Neogen Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.44 B | 4.55 B | 4.55 B | 993 M | 920 M | 797 M | 696 M | 618 M | 528 M | 452 M | 392 M | 345 M | 291 M | 252 M | 220 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.55 B | 220 M | 1.27 B |
Quarterly Total Assets Neogen Corporation
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.36 B | 3.38 B | 3.44 B | 4.04 B | 4.05 B | 4.5 B | 4.55 B | 4.58 B | 4.6 B | 4.56 B | 4.55 B | 4.51 B | 4.56 B | 977 M | 993 M | 981 M | 968 M | 932 M | 920 M | 920 M | 846 M | 822 M | 846 M | 774 M | 751 M | 721 M | 751 M | 721 M | 660 M | 641 M | 660 M | 641 M | 581 M | 547 M | 581 M | 547 M | 487 M | 469 M | 487 M | 469 M | 426 M | 409 M | 426 M | 409 M | 366 M | 358 M | 366 M | 358 M | 320 M | 308 M | 320 M | 308 M | 270 M | 261 M | 270 M | 261 M | 234 M | 228 M | 234 M | 228 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.6 B | 228 M | 1.35 B |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
94.3 M | $ 13.73 | 0.59 % | $ 99.4 M |  Israel |
 |
Aspira Women's Health
AWH
|
17.4 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Bioventus
BVS
|
684 M | $ 8.99 | 1.35 % | $ 599 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M |  Britain |
 |
CareDx, Inc
CDNA
|
413 M | $ 17.6 | 1.62 % | $ 938 M | USA |
 |
Charles River Laboratories International
CRL
|
7.14 B | $ 153.71 | 1.14 % | $ 7.62 B | USA |
 |
Castle Biosciences
CSTL
|
531 M | $ 25.9 | 0.27 % | $ 719 M | USA |
 |
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M | USA |
 |
DexCom
DXCM
|
6.34 B | $ 67.32 | 1.48 % | $ 26.3 B | USA |
 |
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | China |
 |
Exact Sciences Corporation
EXAS
|
5.86 B | $ 103.94 | 0.09 % | $ 19.6 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | USA |
 |
Fulgent Genetics
FLGT
|
1.22 B | $ 15.43 | 3.21 % | $ 467 M | USA |
|
Biodesix
BDSX
|
97.2 M | $ 16.59 | -4.05 % | $ 2.15 B | USA |
 |
Anixa Biosciences
ANIX
|
16.1 M | $ 2.89 | 1.76 % | $ 93.8 K | USA |
 |
Guardant Health
GH
|
2.01 B | $ 88.75 | 1.8 % | $ 11.1 B | USA |
 |
Danaher Corporation
DHR
|
83.5 B | $ 195.21 | 2.0 % | $ 139 B | USA |
 |
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
16.9 B | $ 100.49 | 2.95 % | $ 8.29 B |  Irlanda |
 |
Illumina
ILMN
|
6.3 B | $ 120.84 | 1.31 % | $ 19.2 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 198.61 | -0.17 % | $ 22 B | USA |
 |
QIAGEN N.V.
QGEN
|
5.69 B | - | - | $ 10.6 B |  Niderland |
 |
IQVIA Holdings
IQV
|
29.9 B | $ 168.43 | 2.15 % | $ 29 B | USA |
 |
Agilent Technologies
A
|
10.7 B | $ 112.75 | 0.82 % | $ 34.3 B | USA |
 |
BioNano Genomics
BNGO
|
76.7 M | $ 1.13 | 1.8 % | $ 1.44 M | USA |
 |
DarioHealth Corp.
DRIO
|
96.4 M | $ 8.75 | 3.92 % | $ 248 M | Israel |
 |
Lantheus Holdings
LNTH
|
2.23 B | $ 80.45 | 2.48 % | $ 5.43 B | USA |
 |
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
377 K | - | - | $ 9.42 M | Israel |
 |
Co-Diagnostics
CODX
|
95.3 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
1.98 B | $ 455.15 | 0.33 % | $ 13.1 B | USA |
 |
Celcuity
CELC
|
245 M | $ 114.11 | -0.69 % | $ 4.5 B | USA |
 |
Motus GI Holdings
MOTS
|
7.22 M | - | -34.28 % | $ 263 K | Israel |
 |
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | USA |
 |
Mettler-Toledo International
MTD
|
3.71 B | $ 1 206.72 | 0.63 % | $ 24.9 B |  Schweiz |
 |
NeoGenomics
NEO
|
1.36 B | $ 8.27 | 0.36 % | $ 1.06 B | USA |
 |
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | USA |
 |
National Research Corporation
NRC
|
135 M | $ 17.73 | 1.9 % | $ 397 M | USA |
 |
Natera
NTRA
|
1.39 B | $ 198.38 | 0.35 % | $ 19.5 B | USA |
 |
Invitae Corporation
NVTA
|
1.95 B | - | - | $ 21.2 M | USA |
 |
Myriad Genetics
MYGN
|
707 M | $ 4.78 | 4.14 % | $ 443 M | USA |
 |
OPKO Health
OPK
|
2.2 B | $ 1.19 | - | $ 826 M | USA |